Babak Jalilian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Babak Jalilian has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Vorup-Jensen
Department of Biomedicine, Aarhus University, Aarhus C, Denmark
6 shared publications - Bent Deleuran
Department of Biomedicine Aarhus University Aarhus Denmark
2 shared publications - Halldór Bjarki Einarsson
Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark
2 shared publications - Stig Hill Christiansen
Department of Biomedicine, Aarhus University, Aarhus C, Denmark
2 shared publications - Tue Wenzel Kragstrup
Department of Biomedicine Aarhus University Aarhus Denmark
2 shared publications A. Omar
1 shared publication
Latest Publications
- 1 March 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1859 (3) , 425-437
The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage
- 1 March 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1859 (3) , 425-437
The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage
- Open Access
- 5 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148486
Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response
In rheumatoid arthritis (RA) immune activation and presence of autoantibodies may precede clinical onset of disease, and joint destruction can progress despite remission. However, the underlying temporal changes of such immune system abnormalities in the inflammatory response during treat-to-target strategies remain poorly understood. We have previously reported low levels of the soluble form of CD18 (sCD18) in plasma from patients with chronic RA and spondyloarthritis. Here, we study the changes of sCD18 before and during treatment of early RA and following arthritis induction in murine models of rheumatoid arthritis. The level of sCD18 was analyzed with a time-resolved immunoflourometric assay in 1) plasma from early treatment naïve RA patients during a treat-to-target strategy (the OPERA cohort), 2) plasma from chronic RA patients, 3) serum from SKG and CIA mice following arthritis induction, and 4) supernatants from synovial fluid mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) from 6 RA patients cultured with TNFα or adalimumab. Plasma levels of sCD18 were decreased in chronic RA patients compared with early RA patients and in early RA patients compared with healthy controls. After 12 months of treatment the levels in early RA patients were similar to healthy controls. This normalization of plasma sCD18 levels was more pronounced in patients with very early disease who achieved an early ACR response. Plasma sCD18 levels were associated with radiographic progression. Correspondingly, the serum level of sCD18 was decreased in SKG mice 6 weeks after arthritis induction compared with healthy littermates. The sCD18 levels in both SKG and CIA mice exhibited a biphasic course after arthritis induction with an initial increase above baseline followed by a decline. Shedding of CD18 from RA SFMC and RA PBMC cultures was increased by TNFα and decreased by adalimumab. The plasma sCD18 levels were altered in patients with RA, in mice with autoimmune arthritis and in cell cultures treated with TNFα and adalimumab. Decreased levels of plasma sCD18 could reflect autoimmunity in transition from early to chronic disease and normalization in response to treatment could reflect autoimmunity in remission.
- 5 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0148486
Open AccessChanges in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response
In rheumatoid arthritis (RA) immune activation and presence of autoantibodies may precede clinical onset of disease, and joint destruction can progress despite remission. However, the underlying temporal changes of such immune system abnormalities in the inflammatory response during treat-to-target strategies remain poorly understood. We have previously reported low levels of the soluble form of CD18 (sCD18) in plasma from patients with chronic RA and spondyloarthritis. Here, we study the changes of sCD18 before and during treatment of early RA and following arthritis induction in murine models of rheumatoid arthritis. The level of sCD18 was analyzed with a time-resolved immunoflourometric assay in 1) plasma from early treatment naïve RA patients during a treat-to-target strategy (the OPERA cohort), 2) plasma from chronic RA patients, 3) serum from SKG and CIA mice following arthritis induction, and 4) supernatants from synovial fluid mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) from 6 RA patients cultured with TNFα or adalimumab. Plasma levels of sCD18 were decreased in chronic RA patients compared with early RA patients and in early RA patients compared with healthy controls. After 12 months of treatment the levels in early RA patients were similar to healthy controls. This normalization of plasma sCD18 levels was more pronounced in patients with very early disease who achieved an early ACR response. Plasma sCD18 levels were associated with radiographic progression. Correspondingly, the serum level of sCD18 was decreased in SKG mice 6 weeks after arthritis induction compared with healthy littermates. The sCD18 levels in both SKG and CIA mice exhibited a biphasic course after arthritis induction with an initial increase above baseline followed by a decline. Shedding of CD18 from RA SFMC and RA PBMC cultures was increased by TNFα and decreased by adalimumab. The plasma sCD18 levels were altered in patients with RA, in mice with autoimmune arthritis and in cell cultures treated with TNFα and adalimumab. Decreased levels of plasma sCD18 could reflect autoimmunity in transition from early to chronic disease and normalization in response to treatment could reflect autoimmunity in remission.
- Open Access
- 26 January 2016
- Published by River Publishers in Molecular and Cellular Therapies
- Vol. 4 (1) , 1
Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules
Psoriasis is an inflammatory disease characterized by leukocyte skin infiltration. Interestingly, recent works suggest that the migration of dendritic cells (DCs) is abnormal in psoriatic skin. DCs have significant role in regulating the function of T lymphocytes, at least in part influenced by the local environment of cytokines. In psoriatic skin lesions the expression of IL-20 is highly up-regulated. It is unclear if this cytokine has any influence on DCs.
- 26 January 2016
- Published by River Publishers in Molecular and Cellular Therapies
- Vol. 4 (1) , 1
Open AccessInterleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules
Psoriasis is an inflammatory disease characterized by leukocyte skin infiltration. Interestingly, recent works suggest that the migration of dendritic cells (DCs) is abnormal in psoriatic skin. DCs have significant role in regulating the function of T lymphocytes, at least in part influenced by the local environment of cytokines. In psoriatic skin lesions the expression of IL-20 is highly up-regulated. It is unclear if this cytokine has any influence on DCs.
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 373
THU0550 Changes in Soluble CD18 Reflect Latency in Restoration of the Immune System after Early Treatment of Rheumatoid Arthritis
Background In rheumatoid arthritis (RA) immune activation and leukocyte migration to the joints precede clinical onset of disease. Early inhibition of inflammation is the main aim of treat-to-target strategy, but the mechanisms and time course for restoration of the immune system remains poorly understood. The family of CD18 integrins is central in the inflammatory response by allowing leukocytes to bind ICAM-1 and migrate to inflammatory foci. We have demonstrated a soluble form of CD18 (sCD18), which is shed to the systemic circulation by monocytes and increased following stimulation with TNFα. sCD18 competes with the cell-expressed receptors for binding to ICAM-1 and thus may function by limiting leukocyte adhesion to ICAM-1.(1) Recently, we found that plasma levels of sCD18 are decreased because of binding to inflammation induced ICAM-1 and associate inversely with disease activity in chronic spondyloarthritis.(2) Objectives To characterize the profile and regulation of plasma sCD18 levels in patients with early rheumatoid arthritis before and during a treat-to-target strategy (the OPERA regimen). Methods The level of sCD18 in plasma was analyzed with a time-resolved immunoflourometric assay (TRIFMA) in a study population of 152 patients with early treatment naïve RA (the OPERA cohort) at baseline and after 3, 6, and 12 months of treatment with methotrexate + placebo (PLA) or methotrexate + adalimumab (ADA) and matched healthy controls (HC). In vitro, synovial fluid mononuclear cells (SFMC) and peripheral blood mononuclear cells (PBMC) from 9 RA patients were cultured with or without adalimumab (5μg/ml) for 48 hours. Results Plasma levels of sCD18 were decreased in early RA patients at baseline (median=958mU/ml, IQR=766-1243mU/ml) compared with HC (median=1001mU/ml, IQR=872-1355mU/ml) (PPP=0.6). RA patients with an ACR70 response or EULAR DAS response after 3 months of treatment had a greater increase in sCD18 plasma levels from baseline to 12 months (both PPPConclusions The decreased plasma levels of sCD18 could be part of the deregulated immune system in early RA. Interestingly, sCD18 exhibited a biphasic course during a treat-to-target strategy with an initial decline followed by a gradual increase to HC levels. In vitro, adalimumab decreased the CD18 shedding explaining the initial decrease in sCD18 plasma levels. The late increase found especially in the patients with an early ACR70 response or EULAR DAS response could reflect latency in restoration of the normal immune system, pointing to sCD18 as a marker for such restoration. References Gjelstrup LC et al., J. Immunol., 2010 Oct. Kragstrup TW et al., Arthritis Res Ther, 2014 Jan (accepted). Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5732
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 373
THU0550 Changes in Soluble CD18 Reflect Latency in Restoration of the Immune System after Early Treatment of Rheumatoid Arthritis
Background In rheumatoid arthritis (RA) immune activation and leukocyte migration to the joints precede clinical onset of disease. Early inhibition of inflammation is the main aim of treat-to-target strategy, but the mechanisms and time course for restoration of the immune system remains poorly understood. The family of CD18 integrins is central in the inflammatory response by allowing leukocytes to bind ICAM-1 and migrate to inflammatory foci. We have demonstrated a soluble form of CD18 (sCD18), which is shed to the systemic circulation by monocytes and increased following stimulation with TNFα. sCD18 competes with the cell-expressed receptors for binding to ICAM-1 and thus may function by limiting leukocyte adhesion to ICAM-1.(1) Recently, we found that plasma levels of sCD18 are decreased because of binding to inflammation induced ICAM-1 and associate inversely with disease activity in chronic spondyloarthritis.(2) Objectives To characterize the profile and regulation of plasma sCD18 levels in patients with early rheumatoid arthritis before and during a treat-to-target strategy (the OPERA regimen). Methods The level of sCD18 in plasma was analyzed with a time-resolved immunoflourometric assay (TRIFMA) in a study population of 152 patients with early treatment naïve RA (the OPERA cohort) at baseline and after 3, 6, and 12 months of treatment with methotrexate + placebo (PLA) or methotrexate + adalimumab (ADA) and matched healthy controls (HC). In vitro, synovial fluid mononuclear cells (SFMC) and peripheral blood mononuclear cells (PBMC) from 9 RA patients were cultured with or without adalimumab (5μg/ml) for 48 hours. Results Plasma levels of sCD18 were decreased in early RA patients at baseline (median=958mU/ml, IQR=766-1243mU/ml) compared with HC (median=1001mU/ml, IQR=872-1355mU/ml) (PPP=0.6). RA patients with an ACR70 response or EULAR DAS response after 3 months of treatment had a greater increase in sCD18 plasma levels from baseline to 12 months (both PPPConclusions The decreased plasma levels of sCD18 could be part of the deregulated immune system in early RA. Interestingly, sCD18 exhibited a biphasic course during a treat-to-target strategy with an initial decline followed by a gradual increase to HC levels. In vitro, adalimumab decreased the CD18 shedding explaining the initial decrease in sCD18 plasma levels. The late increase found especially in the patients with an early ACR70 response or EULAR DAS response could reflect latency in restoration of the normal immune system, pointing to sCD18 as a marker for such restoration. References Gjelstrup LC et al., J. Immunol., 2010 Oct. Kragstrup TW et al., Arthritis Res Ther, 2014 Jan (accepted). Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5732
- Open Access
- 4 February 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (1) , R42
Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis
Introduction: Spondyloarthritis (SpA) comprises a group of diseases often associated with HLA-B27 and characterized by inflammation of the entheses and joints of the axial skeleton. The inflammatory process in SpA is presumably driven by innate immune cells but is still poorly understood. Thus, new tools for monitoring and treating inflammation are needed. The family of CD18 integrins is pivotal in guiding leukocytes to sites of inflammation, and CD18 hypomorphic mice develop a disease resembling SpA. Previously, we demonstrated that altered soluble CD18 (sCD18) complexes in the blood and synovial fluid of patients with arthritis have anti-inflammatory functions. Here, we study the mechanisms for these alterations and their association with SpA disease activity. Methods: Plasma levels of sCD18 in a study population with 84 patients with SpA and matched healthy controls were analyzed with a time-resolved immunoflourometric assay (TRIFMA). Binding of sCD18 to endothelial cells and fibroblast-like synoviocytes (FLSs) was studied with confocal microscopy. Shedding of CD18 from peripheral blood mononuclear cells (PBMCs) was studied with flow cytometry and TRIFMA. Results: Plasma levels of sCD18 were decreased in patients with SpA compared with healthy volunteers (P P P P P P P in vitro. First, sCD18 in plasma adhered to inflammation-induced intercellular adhesion molecule 1 (ICAM-1) on endothelial cells and FLS, indicating increased consumption. Second, CD18 shedding from SpA PBMCs correlated inversely with the BASDAI (P ++ CD16+ monocytes, supporting the view that alterations in innate immunity can regulate the inflammatory processes in SpA. Conclusions: Taken together, the failure of patients with SpA to maintain adequate sCD18 levels may reflect insufficient CD18 shedding from monocytes to counterbalance the capture of sCD18 complexes to inflammation-induced ICAM-1. This could increase the availability of ICAM-1 molecules on the endothelium and in the synovium, facilitating leukocyte migration to the entheses and joints and aggregating disease activity.
- 4 February 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (1) , R42
Open AccessDecreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis
Introduction: Spondyloarthritis (SpA) comprises a group of diseases often associated with HLA-B27 and characterized by inflammation of the entheses and joints of the axial skeleton. The inflammatory process in SpA is presumably driven by innate immune cells but is still poorly understood. Thus, new tools for monitoring and treating inflammation are needed. The family of CD18 integrins is pivotal in guiding leukocytes to sites of inflammation, and CD18 hypomorphic mice develop a disease resembling SpA. Previously, we demonstrated that altered soluble CD18 (sCD18) complexes in the blood and synovial fluid of patients with arthritis have anti-inflammatory functions. Here, we study the mechanisms for these alterations and their association with SpA disease activity. Methods: Plasma levels of sCD18 in a study population with 84 patients with SpA and matched healthy controls were analyzed with a time-resolved immunoflourometric assay (TRIFMA). Binding of sCD18 to endothelial cells and fibroblast-like synoviocytes (FLSs) was studied with confocal microscopy. Shedding of CD18 from peripheral blood mononuclear cells (PBMCs) was studied with flow cytometry and TRIFMA. Results: Plasma levels of sCD18 were decreased in patients with SpA compared with healthy volunteers (P P P P P P P in vitro. First, sCD18 in plasma adhered to inflammation-induced intercellular adhesion molecule 1 (ICAM-1) on endothelial cells and FLS, indicating increased consumption. Second, CD18 shedding from SpA PBMCs correlated inversely with the BASDAI (P ++ CD16+ monocytes, supporting the view that alterations in innate immunity can regulate the inflammatory processes in SpA. Conclusions: Taken together, the failure of patients with SpA to maintain adequate sCD18 levels may reflect insufficient CD18 shedding from monocytes to counterbalance the capture of sCD18 complexes to inflammation-induced ICAM-1. This could increase the availability of ICAM-1 molecules on the endothelium and in the synovium, facilitating leukocyte migration to the entheses and joints and aggregating disease activity.
- Open Access
- 1 January 2013
- Published by River Publishers in Molecular and Cellular Therapies
- Vol. 1 (1) , 2
Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?
Influenza is a major challenge to healthcare systems world-wide. While prophylactic vaccination is largely efficient, long-lasting immunity has not been achieved in immunized populations, at least in part due to the challenges arising from the antigen variation between strains of influenza A virus as a consequence of genetic drift and shift. From progress in our understanding of the immune system, the mode-of-action of vaccines can be divided into the stimulation of the adaptive system through inclusion of appropriate vaccine antigens and of the innate immune system by the addition of adjuvant to the vaccine formulation. A shared property of many vaccine adjuvants is found in their nature of water-insoluble precipitates, for instance the particulate material made from aluminum salts. Previously, it was thought that embedding of vaccine antigens in these materials provided a "depot" of antigens enabling a long exposure of the immune system to the antigen. However, more recent work points to a role of particulate adjuvants in stimulating cellular parts of the innate immune system. Here, we briefly outline the infectious medicine and immune biology of influenza virus infection and procedures to provide sufficient and stably available amounts of vaccine antigen. This is followed by presentation of the many roles of adjuvants, which involve humoral factors of innate immunity, notably complement. In a perspective of the ultrastructural properties of these humoral factors, it becomes possible to rationalize why these insoluble precipitates or emulsions are such a provocation of the immune system. We propose that the biophysics of particulate material may hold opportunities that could aid the development of more efficient influenza vaccines.
- 1 January 2013
- Published by River Publishers in Molecular and Cellular Therapies
- Vol. 1 (1) , 2
Open AccessProperties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?
Influenza is a major challenge to healthcare systems world-wide. While prophylactic vaccination is largely efficient, long-lasting immunity has not been achieved in immunized populations, at least in part due to the challenges arising from the antigen variation between strains of influenza A virus as a consequence of genetic drift and shift. From progress in our understanding of the immune system, the mode-of-action of vaccines can be divided into the stimulation of the adaptive system through inclusion of appropriate vaccine antigens and of the innate immune system by the addition of adjuvant to the vaccine formulation. A shared property of many vaccine adjuvants is found in their nature of water-insoluble precipitates, for instance the particulate material made from aluminum salts. Previously, it was thought that embedding of vaccine antigens in these materials provided a "depot" of antigens enabling a long exposure of the immune system to the antigen. However, more recent work points to a role of particulate adjuvants in stimulating cellular parts of the innate immune system. Here, we briefly outline the infectious medicine and immune biology of influenza virus infection and procedures to provide sufficient and stably available amounts of vaccine antigen. This is followed by presentation of the many roles of adjuvants, which involve humoral factors of innate immunity, notably complement. In a perspective of the ultrastructural properties of these humoral factors, it becomes possible to rationalize why these insoluble precipitates or emulsions are such a provocation of the immune system. We propose that the biophysics of particulate material may hold opportunities that could aid the development of more efficient influenza vaccines.
- Open Access
- 9 November 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (11) , 14579-14605
Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?
Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now play a significant role in ameliorating the disease. Glatiramer acetate (GA) is a formulation of random polypeptide copolymers for the treatment of relapsing-remitting MS by limiting the frequency of attacks. While evidence suggests the influence of GA on inflammatory responses, the targeted molecular mechanisms remain poorly understood. Here, we review the multiple pharmacological modes-of-actions of glatiramer acetate in treatment of multiple sclerosis. We discuss in particular a newly discovered interaction between the leukocyte-expressed integrin αMβ2 (also called Mac-1, complement receptor 3, or CD11b/CD18) and perspectives on the GA co-polymers as an influence on the function of the innate immune system.
- 9 November 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (11) , 14579-14605
Open AccessGlatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?
Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now play a significant role in ameliorating the disease. Glatiramer acetate (GA) is a formulation of random polypeptide copolymers for the treatment of relapsing-remitting MS by limiting the frequency of attacks. While evidence suggests the influence of GA on inflammatory responses, the targeted molecular mechanisms remain poorly understood. Here, we review the multiple pharmacological modes-of-actions of glatiramer acetate in treatment of multiple sclerosis. We discuss in particular a newly discovered interaction between the leukocyte-expressed integrin αMβ2 (also called Mac-1, complement receptor 3, or CD11b/CD18) and perspectives on the GA co-polymers as an influence on the function of the innate immune system.
- Open Access
- 24 May 2010
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 8 (1) , 4
Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovisas genetic adjuvant
Background: Studies have shown that DNA vaccines can induce protective immunity, which demonstrated the high potential of DNA vaccines as an alternative to inactivated vaccines. Vaccines are frequently formulated with adjuvants to improve their release, delivery and presentation to the host immune system.Methods: The H5 gene of H5N1 virus (A/Ck/Malaysia/5858/04) was cloned separately into pcDNA3.1 + vector. The immunogenicity of the cloned H5 DNA vaccine was tested on SPF chickens using two different approaches. First approach was using H5 DNA vaccine (pcDNA3.1/H5) and the second was using H5 DNA vaccine in addition to the pcDNA3.1/MDP1 vaccine. Ten days old chickens inoculated three times with two weeks intervals. The spleen and muscle samples from chickens immunized with H5 (pcDNA3.1/H5) and H5 + MDP1 (pcDNA3.1/H5 + pcDNA3.1/MDP1) vaccines were collected after sacrificing the chickens and successfully expressed H5 and MDP1 RNA transcripts. The sera of immunized chickens were collected prior to first immunization and every week after immunization; and analyzed using enzyme-linked immunosorbent assay (ELISA) and hemagglutination inhibition (HI) test.Results: Results of competitive ELISA showed successful antibody responses two weeks post immunization. The HI test showed an increased in antibody titers during the course of experiment in group immunized with H5 and H5 + MDP1 vaccines. The result showed that the constructed DNA vaccines were able to produce detectable antibody titer in which the group immunized with H5 + MDP1 vaccine produced higher antibody comparing to H5 vaccine alone.Conclusions: This study shows for the first time the usefulness of MDP1 as a genetic adjuvant for H5 DNA vaccine.
- 24 May 2010
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 8 (1) , 4
Open AccessDevelopment of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovisas genetic adjuvant
Background: Studies have shown that DNA vaccines can induce protective immunity, which demonstrated the high potential of DNA vaccines as an alternative to inactivated vaccines. Vaccines are frequently formulated with adjuvants to improve their release, delivery and presentation to the host immune system.Methods: The H5 gene of H5N1 virus (A/Ck/Malaysia/5858/04) was cloned separately into pcDNA3.1 + vector. The immunogenicity of the cloned H5 DNA vaccine was tested on SPF chickens using two different approaches. First approach was using H5 DNA vaccine (pcDNA3.1/H5) and the second was using H5 DNA vaccine in addition to the pcDNA3.1/MDP1 vaccine. Ten days old chickens inoculated three times with two weeks intervals. The spleen and muscle samples from chickens immunized with H5 (pcDNA3.1/H5) and H5 + MDP1 (pcDNA3.1/H5 + pcDNA3.1/MDP1) vaccines were collected after sacrificing the chickens and successfully expressed H5 and MDP1 RNA transcripts. The sera of immunized chickens were collected prior to first immunization and every week after immunization; and analyzed using enzyme-linked immunosorbent assay (ELISA) and hemagglutination inhibition (HI) test.Results: Results of competitive ELISA showed successful antibody responses two weeks post immunization. The HI test showed an increased in antibody titers during the course of experiment in group immunized with H5 and H5 + MDP1 vaccines. The result showed that the constructed DNA vaccines were able to produce detectable antibody titer in which the group immunized with H5 + MDP1 vaccine produced higher antibody comparing to H5 vaccine alone.Conclusions: This study shows for the first time the usefulness of MDP1 as a genetic adjuvant for H5 DNA vaccine.
- 1 January 2010
- Published by Frontiers Media SA in Acta Virologica
- Vol. 54 (1) , 33-39
Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency
Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency
- 1 January 2010
- Published by Frontiers Media SA in Acta Virologica
- Vol. 54 (1) , 33-39
Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency
Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency